95
Views
1
CrossRef citations to date
0
Altmetric
Original Article

Lack of association between the C2 allele of transferrin and age-related macular degeneration in the Israeli population

, , , , , , , , & show all
Pages 161-164 | Received 24 Feb 2009, Accepted 20 Jun 2009, Published online: 23 Oct 2009

REFERENCES

  • He X, Hahn P, Iacovelli J, et al. Iron homeostasis and toxicity in retinal degeneration. Prog Retin Eye Res. 2007;26:649–673.
  • Lehmann DJ, Worwood M, Ellis R, et al. Iron genes, iron load and risk of Alzheimer’s disease. J Med Genet. 2006;43:e52.
  • Hahn P, Milam AH, Dunaief JL. Maculas affected by age-related macular degeneration contain increased chelatable iron in the retinal pigment epithelium and Bruch’s membrane. Arch Ophthalmol. 2003;121:1099–1105.
  • Dunaief JL, Richa C, Franks EP, et al. Macular degeneration in a patient with aceruloplasminemia, a disease associated with retinal iron overload. Ophthalmology. 2005;112:1062–1065.
  • Hahn P, Chen L, Beard J, Harris Z, Dunaief J. Disruption of ceruloplasmin and hephaestin in mice causes retinal iron overload and retinal degeneration with features of age-related macular degeneration. Invest Ophthalmol Vis Sci. 2004;45:E-Abstract 2292.
  • Hadziahmetovic M, Dentchev T, Song Y, et al. Ceruloplasmin/hephaestin knockout mice model morphologic and molecular features of AMD. Invest Ophthalmol Vis Sci. 2008;49:2728–2736.
  • Chowers I, Wong R, Dentchev T, et al. The iron carrier transferrin is upregulated in retinas from patients with age-related macular degeneration. Invest Ophthalmol Vis Sci. 2006;47:2135–2140.
  • Chowers I, Gunatilaka T, Farkas R, et al. Identification of novel genes preferentially expressed in the retina using a custom human retina cDNA microarray. Invest Ophthalmol Vis Sci. 2003;44:3732–3741.
  • Picard E, Fontaine I, Jonet L, et al. The protective role of transferrin in Muller glial cells after iron-induced toxicity. Mol Vis. 2008;14:928–941.
  • Escobar Cabrera OE, Zakin MM, Soto EF, Pasquini JM. Single intracranial injection of apotransferrin in young rats increases the expression of specific myelin protein mRNA. J Neurosci Res. 1997;47:603–608.
  • Hyndman AG, Hockberger PE, Zeevalk GD, Connor JA. Transferrin can alter physiological properties of retinal neurons. Brain Res. 1991;561:318–323.
  • Namekata K, Imagawa M, Terashi A, Ohta S, Oyama F, Ihara Y. Association of transferrin C2 allele with late-onset Alzheimer’s disease. Hum Genet. 1997;101:126–129.
  • Van Rensburg SJ, Carstens ME, Potocnik FC, van der Spuy G, van der Walt BJ, Taljaard JJ. Transferrin C2 and Alzheimer’s disease: another piece of the puzzle found? Med Hypotheses. 1995;44:268–272.
  • Van Landeghem GF, Sikstrom C, Beckman LE, Adolfsson R, Beckman L. Transferrin C2, metal binding and Alzheimer’s disease. Neuroreport. 1998;9:177–179.
  • van Rensburg SJ, Potocnik FC, De Villiers JN, Kotze MJ, Taljaard JJ. Earlier age of onset of Alzheimer’s disease in patients with both the transferrin C2 and apolipoprotein E-epsilon 4 alleles. Ann N Y Acad Sci. 2000;903:200–203.
  • van Rensburg SJ, Carstens ME, Potocnik FC, Aucamp AK, Taljaard JJ. Increased frequency of the transferrin C2 subtype in Alzheimer’s disease. Neuroreport. 1993;4:1269–1271.
  • Zambenedetti P, De Bellis G, Biunno I, Musicco M, Zatta P. Transferrin C2 variant does confer a risk for Alzheimer’s disease in caucasians. J Alzheimers Dis. 2003;5:423–427.
  • Lleo A, Blesa R, Angelopoulos C, et al. Transferrin C2 allele, haemochromatosis gene mutations, and risk for Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2002;72:820–821.
  • Kim KW, Jhoo JH, Lee JH, et al. Transferrin C2 variant does not confer a risk for Alzheimer’s disease in Koreans. Neurosci Lett. 2001;308:45–48.
  • Hussain RI, Ballard CG, Edwardson JA, Morris CM. Transferrin gene polymorphism in Alzheimer’s disease and dementia with Lewy bodies in humans. Neurosci Lett. 2002;317:13–16.
  • Robson KJ, Lehmann DJ, Wimhurst VL, et al. Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer’s disease. J Med Genet. 2004;41:261–265.
  • Edwards AO. Genetics of age-related macular degeneration. Adv Exp Med Biol. 2008;613:211–219.
  • A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119:1417–1436.
  • Jouanolle AM, Gandon G, Jezequel P, et al. Haemochromatosis and HLA-H. Nat Genet. 1996;14:251–252.
  • Dentchev T, Hahn P, Dunaief JL. Strong labeling for iron and the iron-handling proteins ferritin and ferroportin in the photoreceptor layer in age-related macular degeneration. Arch Ophthalmol. 2005;123:1745–1746.
  • Beckman L, Beckman G. Transferrin C2 as an enhancer of cyto- and genotoxic damage. Prog Clin Biol Res. 1986;209B:221–224.
  • Zatta P, Messori L, Mauri P, et al. The C2 variant of human serum transferrin retains the iron binding properties of the native protein. Biochim Biophys Acta. 2005;1741:264–270.
  • Goland S, Beilinson N, Kaftouri A, Shimoni S, Caspi A, Malnick SD. Hemochromatosis mutations are not linked to dilated cardiomyopathy in Israeli patients. Eur J Heart Fail. 2004;6:547–550.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.